Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:30 PM
Ignite Modification Date:
2025-12-24 @ 9:30 PM
NCT ID:
NCT06777732
Eligibility Criteria:
Inclusion Criteria:
1. Ages 18-65
2. Patients who tested positive for H. pylori by 13C or 14C breath test and have not received previous eradication therapy
3. Voluntarily join the trial and sign the informed consent form.
Exclusion Criteria:
1. Allergic to the study drug (e.g. penicillin allergy)
2. Recent bleeding or within 4 weeks of bleeding history in the stomach or duodenum
3. Patients who have previously received eradication therapy for Helicobacter pylori
4. Use antibiotics or bismuth medication 4 weeks before starting the study；use P-CAB or PPI 2 weeks before starting the study
5. Patients who have had surgery on the stomach or intestines, which affects the drug's metabolism
6. Pregnant or lactating women
7. Patients with other serious physiological or psychological conditions, or those with liver or kidney dysfunction
8. Patients with Zollinger-Ellison syndrome, gastric mucosal-associated lymphoid tissue lymphoma (MALT), or malignant tumors
9. Patients with glucose-6-phosphate dehydrogenase (G-6PD) deficiency, peptic ulcer disease, or bronchial asthma
10. Patients with concomitant medications including azatanavir or lopinavir, tricyclic antidepressants, levodopa, paracetamol, codeine phosphate/dextromethorphan, monoamine oxidase inhibitors, tramadol, etc.
11. Other factors that the investigator considers unsuitable for participation in the study, etc.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT06777732
Study Brief:
Protocol Section:
NCT06777732